Elimination of Albumin-Bound Substances by MARS and Prometheus

Medical University of Graz10 enrolled

Overview

This trial compares the efficacy of two artificial liver support systems, MARS (Molecular Adsorbents Recirculating System) and Prometheus (FPSA, Fractionated Plasma Separation and Adsorption), in removing albumin-bound substances such as bilirubin, bile acids, and cytokines.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Liver Failure

Interventions

MARS (Molecular Adsorbents Recirculating System)DEVICE

Prometheus (FPSA, Fractionated Plasma Separation and Adsorption)DEVICE

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * consecutive patients with acute-on-chronic liver failure (severe deterioration of chronic liver disease) unresponsive to standard medical treatment for \>=48 hours Exclusion Criteria: * arterial hypotension * extrahepatic malignancy

Locations (1)

Medical University of Graz

Graz, Austria

Outcomes

Primary Outcomes

serum levels of albumin-bound substances

Secondary Outcomes

plasma clearance of albumin-bound substances

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.